🇺🇸 FDA
Patent

US 10519222

Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region

granted A61KA61K39/42A61K45/06

Quick answer

US patent 10519222 (Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K39/42, A61K45/06, A61P, A61P31/18